fashion -WSS

fashion

author：focus 2025-09-27 23:52:49 - browse：72297

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Novo Nordisk obesity pill bests Wegovy in early trial

WSS

New report analyzes digital physical therapy solutions' effectiveness

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Medical device trials still don't enroll enough women, study finds

Amylyx ALS drug fails large clinical trial

How faith leaders like me can help address America's obesity epidemic

STAT Virtual Event: ASCO Recap, Live!

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

5 takeaways from STAT's examination of Zynex Medical

In age of alternative facts, a scholarly course on calling out crap

Curing rare childhood diseases will falter unless Congress steps up

Walensky prepares to leave CDC — and Congress — behind

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Sports medicine is finally prioritizing gender equality

What it’s like to watch children die of measles

23andMe had bad news about my health. I wish a person had delivered it

Amylyx ALS drug failure raises questions and concerns

entertainment

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Report captures long Covid’s disabling effects and policy challenges

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

My daughter's legacy lives on through her writing, phage therapy

New report analyzes digital physical therapy solutions' effectiveness

leisure time

focus

knowledge

knowledge